Afatinib targets particular proteins referred to as EGF receptors in NSCLC cells. This motion stops the most cancers from escalating and spreading. Afatinib belongs to a class of medicines termed tyrosine kinase inhibitors. A category of drugs is a group of medicines that operate in the same way.